Palbociclib (PD-0332991) HCl

Pfizer辉瑞授权 目录号:S1116

Palbociclib (PD-0332991) HCl Chemical Structure

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl是一种高度选择性的CDK4/6抑制剂,无细胞试验中IC50分别为11 nM/16 nM。它对CDK1/2/5,EGFR,FGFR,PDGFR,InsR等没有抑制活性。Phase 3。

规格 价格 库存 购买数量  
RMB 902.49 现货
RMB 1406.17 现货
RMB 4670.26 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的8个实验数据:

  • PD-0332991 causes inhibition of proliferation of EAC cells in a dose-dependent manner. Western blots showing the phosphorylation status of pRB at Ser780 and Ser795 after incubation with 125 nmol/L PD-0332991 for 24 and 72 hours. Reduction in cyclin A expression and the expression of RB2 (p130) tumor suppressor 72 hours after PD-0332991 treatment are shown (bottom). Total pRB (RB1) and actin are loading controls and T293 cell lysate (293) is a positive control for total pRB and phospho-pRB (Ph-RB). E, anchorage-independent growth of the 3 cell lines in the presence or absence (Cnt) of 125 nmol/L PD-0332991 for 3 weeks.

    Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck.

    b, c MelJuso cells were treated for 12–48 h with 1 µM Selumetinib or 5 µM Palbociclib and the cells were fixed, stained with propidium iodide and cell cycle distribution was determined by flow cytometry (b) and whole cell extracts were fractionated by SDS-PAGE, transferred onto PVDF membrane and immuno-blotted with the indicated antibodies (c). Data is from a single experiment representative of three separate experiments with similar results. The data in (b) are mean ± S.D. from a single experiment with three replicate dishes of cell per data point; similar results were obtained in two additional experiments

    Cell Mol Life Sci, 2016, 73(4):883-900. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • (A) Percentage of DN3a cells in S-phase (as gated on DAPI profile) from control (Zfp36l1/2fl/fl) and Zfp36l1/2fl/fl; CD2Cre (DCKO) mice, after 1 d of treatment with vector or palbociclib (drug).

    J Immunol, 2016, 197(7):2673-85. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Patient tumor cell sensitivity to combinatorial treatment with histone deacetylase (HDAC)/cyclin-dependent kinase (CDK) inhibitors in 3-D culture. The effect of each drug or drug combination was assessed by fluorescent dye to identify live (green) and dead cells (red). Cells from breast reduction patients were used as non-cancer control in the assay.

    Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck.

  •  

    Cdk4 is upregulated in ARMS and mMSCs transfected with PAX7-FKHR fusion gene (MP7F), and can be specifi cally inhibited. D: IF results showing overexpression of cdk4 in MP7F cells compared to parental mMSCs and reduced expression of cdk4 after treatment of MP7F cells with the cdk4 inhibitor, PD-0332991. E: IF results showing MyoD1 expression in parental mMSCs cells, and MP7F cells untreated and after treatment with the cdk4 inhibitor, PD-0332991.

    Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck.

    WM3734 melanoma cells were treated by PD-0332991 for 36 hours; melanoma cells treated by Doxorubicin (DXR)  at 0.5 μM is included as a control.

     

     

    Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • Serum-deprived T98G glioma cells are restimulated with serum(FBS) with or without 1 μΜ PD-0332991.

     

     

    Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck.

    P16INK4A knockdown in INK4A/ARF-wt human glioma cell LN319 potentiates PDGF-Apromoted anchorage-dependent growth in vitro. Soft agar growth of Ink4a/Arf-deficient mAst and LN444 cells treated with PD0332991. (A) IB analysis. (B) Quantification of soft agar assays. β-actin was used as a loading control in all IB experiments. Data are presented as mean ± s.d. and representative of two independent experiments. **, P < 0.01; ***, P < 0.001

    Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck.

产品安全说明书

CDK抑制剂选择性比较

生物活性

产品描述 Palbociclib (PD-0332991) HCl是一种高度选择性的CDK4/6抑制剂,无细胞试验中IC50分别为11 nM/16 nM。它对CDK1/2/5,EGFR,FGFR,PDGFR,InsR等没有抑制活性。Phase 3。
特性 PD-0332991作为有应用前景的工具测定CDK激酶是否具有明显的治疗价值。
靶点
CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
9 nM 11 nM 15 nM
体外研究

PD 0332991 对其他蛋白激酶包括EGFR, FGFR, PGFR, IR等没有抑制效果。 PD 0332991作用于Cdk4时是非ATP竞争性抑制剂。PD 0332991抑制MDA-MB-435乳腺癌细胞,IC50为66 nM,是由于Rb 在Ser780的磷酸化作用下降。PD 0332991抑制胸苷合并到Rb阳性的人类乳腺癌,结肠癌 肺癌,及白血病的DNA中,IC50值为4 nM到0.17 μM。PD 0332991作用于Rb阴性细胞没有抑制效果。PD 0332991作用于MDA-MB-453乳腺癌细胞和结肠-205细胞使细胞积累在G1期。[1]PD 0332991也有效作用于骨髓瘤5T33MM细胞,使细胞对Bortezomib敏感。[2]PD 0332991抑制luminalER-阳性和HER2-增强的乳腺癌细胞系,包括MDA-MB-175 ZR-75-30 CAMA-1 MDA-MB-134 HCC-202 UACC-893 等等。在这些细胞系中,PD 0332991增强Tamoxifen和Trastuzumab 的活性。在MCF7抗Tamoxifen细胞中,PD 0332991也增强tamoxifen 的敏感性。[3] 最新研究显示PD 0332991可以抑制恶性横纹肌样肿瘤(MRT)细胞系包括MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS,且MRT细胞系对PD 0332991敏感性和p16表达呈负相关。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 NVLHOnp7U2mwYYPlJGF{e2G7 NHOzUnMzPCCq M1XLfmlvcGmkaYTpc44hd2ZiQ1TLOEBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHJjKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFIh|ryP M2DGeFI1PjRzMUCz
COLO205 MlSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvTcmpIPzJiaB?= MlryRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{\XO|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjB|NjFOwG0> MViyOFY1OTFyMx?=
U937 NUDW[GdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoO2O|IhcA>? NITYepNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMUSg{txO Ml\LNlQ3PDFzMEO=
MOLM13 NYnGS3M2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\ZO|N7PzJiaB?= M3LNcmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV;MUVE{KGOnbHzzJIhiemKxcnnu[{BHVFR|IFnUSEBufXSjboSgZZN{\XO|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjB7NjFOwG0> NUTzN|lQOjR4NEGxNFM>
MOLM13 NGrhO4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4q4VlczKGh? MnKzRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDzc5Ji\mWwaXKtdoV{cXO2YX70JIh2dWGwIF3PUG0yOyClZXzsd{Bie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMEm2JO69VQ>? NYPRbXpCOjR4NEGxNFM>
MDA-MB-435 NYr3e4xCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPIS5kzPCCq MlX6TWM2OD1yLkG2JO69VQ>? NIfifHUyPThyMUizNS=>
K562 MmHpR5l1d3SxeHnjJGF{e2G7 NEfHUnA6PiCq NYX4c4pUTE2VTx?= NEjhb2hKSzVyPUKg{txO M3zRbVI1PDF5NU[2
DU145 MmexR5l1d3SxeHnjJGF{e2G7 NVXtPWNzQTZiaB?= MUXEUXNQ MYXJR|UxRTdwNTFOwG0> MYmyOFQyPzV4Nh?=
MDA-MB-231 M2q0S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHhNUDPxE1? M{K4VlI1KGh? Ml[3SG1UVw>? MlvxR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JGcyKHCqYYPl NUjMOXhFOjR2MUe1OlY>
MCF7 NX3MfnRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\LdHMxOSEQvF2= M3zWb|I1KGh? M{DBTmROW09? NUfPPXpqS2WubDDjfYNt\SCjcoLld5Qh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdzIIDoZZNm MnTZNlQ1OTd3Nk[=
MCF7 MnvWT4lv[XOnIFHzd4F6 MX21JO69VQ>? MWiyOEBp MlvYSG1UVw>? Mn\yTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDDSGs1N2O7Y3zpcmQyKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhemW2aX7vZoxie3SxbXGgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmejd6MB?= M4rGPVI1PDF5NU[2
MDA-MB-231 Mn64T4lv[XOnIFHzd4F6 NHe3OVA2KM7:TR?= M{LiTFI1KGh? M1GzcWROW09? M3v1UmlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgR2RMPC:leXPsbY5FOSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKndHnuc4Jt[XO2b33hJJBpd3OyaH;yfYxifGmxbjDheEBU\XJ5OEC= MlHJNlQ1OTd3Nk[=
MDA-MB-231 NXfZWYsxTnWwY4Tpc44hSXO|YYm= M4jlcVEuOTBizszN NGXZSpMzPCCq M3rYSGROW09? M{GyVYRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYOgZZN{\XO|ZXSgZZMhWEGUUDDjcIVifmGpZR?= NGL0[5gzPDRzN{W2Oi=>
MCF7 NYnlO4t3TnWwY4Tpc44hSXO|YYm= MUCxMVExKM7:TR?= NIriNmIzPCCq Mm\rSG1UVw>? MX\kc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m|IHHzd4V{e2WmIHHzJHBCWlBiY3zlZZZi\2V? MUGyOFQyPzV4Nh?=
MDA-MB-231 NFe0VIRHfW6ldHnvckBCe3OjeR?= NXLZdnJHOC53LUGg{txO MYO0PEBp MV;EUXNQ MlzMbIF{KG6xIFPlcIwh[3mlbHWgZZJz\XO2IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDzeYIuTzFicHjhd4U> NF7pO4czPDRzN{W2Oi=>
MCF7 NHrybppHfW6ldHnvckBCe3OjeR?= NEDnN5kxNjVvMTFOwG0> NH\LPJc1QCCq NETuc3RFVVOR MXLoZZMhdm9iQ3XscEBkgWOuZTDhdpJme3RiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IIP1Zk1IOSCyaHHz[S=> NGT6NYszPDRzN{W2Oi=>
697 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYf6OmprUUN3ME2xOFgvOzhibl2= NUT5N5pQW0GQR1XS
P12-ICHIKAWA M4m4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4j0UGlEPTB;OU[uNFQhdk1? NInQcnBUSU6JRWK=
NB69 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTF4MT64JI5O M4nVWXNCVkeHUh?=
EoL-1 NYTibIV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTF6Nz6yOkBvVQ>? MXrTRW5ITVJ?
BHT-101 MmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXETWM2OD1zOUiuNlUhdk1? MmHDV2FPT0WU
SK-NEP-1 M17OUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3KTWM2OD1{MkCuNFIhdk1? MmPnV2FPT0WU
MHH-NB-11 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PG[2lEPTB;MkKwMlE6KG6P MYnTRW5ITVJ?
AsPC-1 M2i5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXmSoQ1UUN3ME2yOVIvPTNibl2= NWH4bmdwW0GQR1XS
ES1 NVLQTlJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFe3cWRKSzVyPUK1Ok4zPSCwTR?= M{nl[3NCVkeHUh?=
LAMA-84 MlPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTJ3OD6xPUBvVQ>? MUnTRW5ITVJ?
MOLT-16 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ToW2lEPTB;MkW4MlQ6KG6P M2TubHNCVkeHUh?=
ES7 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTrTWM2OD1{N{OuNFkhdk1? NGLQXZRUSU6JRWK=
KY821 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXVfYhKSzVyPUOxOE4yKG6P MlG2V2FPT0WU
RT-112 NIPXT5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTN{MT6wOUBvVQ>? NWjRN5k2W0GQR1XS
HL-60 NE\QXY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljxTWM2OD1|NECuOlYhdk1? MYLTRW5ITVJ?
MOLT-4 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\XV2lEPTB;M{S1MlE{KG6P NUnRNoVFW0GQR1XS
KARPAS-45 M2PlUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjQ[YxKSzVyPUO3Ok4yPiCwTR?= MV3TRW5ITVJ?
SK-N-AS M2DFdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;SUGFKSzVyPUO4O{45OyCwTR?= NFuwWWNUSU6JRWK=
CTB-1 M3zoRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HtbmlEPTB;NEC1MlAzKG6P NXXTUGZPW0GQR1XS
NKM-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTRzMT64PUBvVQ>? MlHZV2FPT0WU
HTC-C3 MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTR|Mj65OUBvVQ>? NY\uRpN7W0GQR1XS
BE-13 NIDTSopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrPZm1[UUN3ME20OFQvOjdibl2= MWrTRW5ITVJ?
KOSC-2 M17ndWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Pn[GlEPTB;NE[2Mlkhdk1? MlHIV2FPT0WU
NB14 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTqfJhkUUN3ME20PFMvPThibl2= MnrYV2FPT0WU
CAL-27 MkHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jwXmlEPTB;NEm0MlU6KG6P NGmwN2RUSU6JRWK=
H9 Mnr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTR7NT60N{BvVQ>? NYHvRY5XW0GQR1XS
RS4-11 NGj6Om1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXKTWM2OD13MESuO|Mhdk1? MXfTRW5ITVJ?
PA-1 NETGTXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDHVIN4UUN3ME21NFkvQDZibl2= NGrYNmdUSU6JRWK=
MV-4-11 NXfBRpo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4H3WWlEPTB;NUGzMlg2KG6P M2PIOHNCVkeHUh?=
OS-RC-2 Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYKyXGw5UUN3ME21NlEvPjJibl2= MVvTRW5ITVJ?
RPMI-8226 NVnWWZZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLJTFBKSzVyPUWyOk45PiCwTR?= MmPHV2FPT0WU
HGC-27 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILMbm5KSzVyPUW2OE46QSCwTR?= M1jnd3NCVkeHUh?=
CHP-212 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vINWlEPTB;NUmzMlU6KG6P Mk[3V2FPT0WU
NB10 NHu1XpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHn4NY1KSzVyPUW5PU4yQCCwTR?= MWLTRW5ITVJ?
HH NUT1UoRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrIXpdOUUN3ME21PVkvPDNibl2= MWnTRW5ITVJ?
EW-16 MnHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DFVWlEPTB;NkCzMlUzKG6P NFfmbJdUSU6JRWK=
ES8 NUPIW4xCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLUTWM2OD14MEWuNlEhdk1? MojDV2FPT0WU
HAL-01 NHXySIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHCSXdEUUN3ME22NFUvPjdibl2= MnzoV2FPT0WU
A204 NGTr[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7QbXpKSzVyPU[zN{46OSCwTR?= NH;LSVBUSU6JRWK=
MHH-PREB-1 MmewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\ERVBKSzVyPU[zOk46QSCwTR?= MmXuV2FPT0WU
EM-2 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfrTWM2OD14NUCuOlQhdk1? MmnCV2FPT0WU
BV-173 MnjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnztTWM2OD14NUKuOFghdk1? M2\NPHNCVkeHUh?=
ONS-76 MoH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjtW5IzUUN3ME22O|cvQDJibl2= NEnROY1USU6JRWK=
KM-H2 NEPMbJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjoZ3NKSzVyPU[5OU42PCCwTR?= M1TmZ3NCVkeHUh?=
D-263MG NVi4NpprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmniTWM2OD15MUeuNVIhdk1? MX3TRW5ITVJ?
ES3 Mk\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\RTWM2OD15MkiuPVMhdk1? MmHmV2FPT0WU
VA-ES-BJ M3X5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPpTWM2OD15M{KuNlchdk1? NVe2eFk2W0GQR1XS
NBsusSR MkD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\4TlJvUUN3ME23OFIvQTlibl2= NH7nSppUSU6JRWK=
NCI-H520 M3flbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTd2Nj61NkBvVQ>? M3XXS3NCVkeHUh?=
ES5 NIqyTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTd3Mj64JI5O MXXTRW5ITVJ?
T-24 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjtcJJsUUN3ME23O|gvPzFibl2= MkjwV2FPT0WU
SW962 NYDMXXpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRThyOD62N{BvVQ>? MlLzV2FPT0WU
EW-3 M1r6OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRThyOD63OkBvVQ>? M1\NVnNCVkeHUh?=
RXF393 NVXw[Jo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rWbWlEPTB;OEGyMlc6KG6P M4L5[XNCVkeHUh?=
U251 NUf2ZWZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRThzMz64PEBvVQ>? M3XvbHNCVkeHUh?=
CAMA-1 M13MbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX34TWpjUUN3ME24N|MvQTRibl2= NYLCZmRSW0GQR1XS
JVM-3 M{\WeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTh3MT63PEBvVQ>? MXXTRW5ITVJ?
COLO-800 NXv2V|d1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTh7Nz63PEBvVQ>? NGPBZYVUSU6JRWK=
OVCAR-5 NXzF[plZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;COYc6UUN3ME25NFAvOSCwTR?= NHnMUXlUSU6JRWK=
LB1047-RCC Mnq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmX0TWM2OD17MkeuOVYhdk1? NXvZWYlFW0GQR1XS
SW954 NFjwdI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTl{OT60NUBvVQ>? MXPTRW5ITVJ?
J-RT3-T3-5 Mn:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LXOGlEPTB;OUO2MlA3KG6P NHnySHZUSU6JRWK=
Mewo MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXi0WYJRUUN3ME25N|YvPiCwTR?= MVvTRW5ITVJ?
NCI-H1770 MoLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\1cJJKSzVyPUm0NE42PSCwTR?= NXrzN5Y1W0GQR1XS
HO-1-N-1 MmKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;KS5RKSzVyPUm2Nk45OSCwTR?= NX\ORVNvW0GQR1XS
HSC-3 NUiwVWc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13BO2lEPTB;OU[2MlQ5KG6P M3fOeHNCVkeHUh?=
TYK-nu M1;lSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MleyTWM2OD17OUiuNlUhdk1? M3f5O3NCVkeHUh?=
KYSE-150 M1r0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LoW2lEPTB;MT6wNFA4PiEQvF2= M4LxN3NCVkeHUh?=
SN12C NUfQN5YxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3yO5NKSzVyPUGuNFA5PzVizszN MnGyV2FPT0WU
MOLT-13 NF;EbllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTFwMEG0NlEh|ryP MXjTRW5ITVJ?
TE-11 NHqyWWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7PbXRKSzVyPUGuNFQ5OTJizszN NHPjN2lUSU6JRWK=
DB NV3CNIdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYH0OGQ2UUN3ME2xMlA4Ojd|IN88US=> NWXWU3BrW0GQR1XS
CAL-39 NV;rWItiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfGeGJKSzVyPUGuNFc2OjJizszN M1zWXXNCVkeHUh?=
A3-KAW M1vSWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHKTWM2OD1zLkC4OFA5KM7:TR?= M13zfHNCVkeHUh?=
CHP-134 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrHTWM2OD1zLkGxPFA4KM7:TR?= Mln6V2FPT0WU
TGW Mn36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTFwMUKzPVUh|ryP NUjBZo82W0GQR1XS
QIMR-WIL MkiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3f5[mlEPTB;MT6xN|E{PCEQvF2= MVTTRW5ITVJ?
NCI-SNU-1 M4X5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHGSmJyUUN3ME2xMlE3OzV2IN88US=> MU\TRW5ITVJ?
CGTH-W-1 NY\DdIxDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWmxXWJpUUN3ME2xMlE4OTh4IN88US=> M4SxPHNCVkeHUh?=
MHH-ES-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\4TWM2OD1zLkG3PVg3KM7:TR?= NVPzOY9XW0GQR1XS
LB2241-RCC NHq5cHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTFwMUi2NkDPxE1? M3\WWnNCVkeHUh?=
ML-2 MoDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvvbXhKSzVyPUGuNlA4OzRizszN MkPHV2FPT0WU
COR-L23 NXL2c4R5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjye29KSzVyPUGuNlI6OzNizszN M1zKdXNCVkeHUh?=
BFTC-905 MnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfrTWM2OD1zLkK0NlY4KM7:TR?= NVTm[lJOW0GQR1XS
Hs-578-T NWf1ZnpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\SR2lEPTB;MT6yOVgyPyEQvF2= M4\HV3NCVkeHUh?=
KG-1 Mlu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTFwMk[2PFYh|ryP M2XCdnNCVkeHUh?=
HEL MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3ITWM2OD1zLkK5N|M5KM7:TR?= Ml\1V2FPT0WU
A549 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnvd3JKSzVyPUGuNlk{QTlizszN Ml\sV2FPT0WU
COLO-741 M2nrfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3GwUWlEPTB;MT6zNlA5QSEQvF2= NXvqOVg4W0GQR1XS
PC-3 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkS0TWM2OD1zLkO1NlIyKM7:TR?= NETCdoZUSU6JRWK=
HOS M3HGd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jrdmlEPTB;MT6zOVI6PiEQvF2= NYrpclhjW0GQR1XS
HT-1080 NELjUnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HvR2lEPTB;MT6zO|UyQSEQvF2= NH\T[FVUSU6JRWK=
TE-8 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPEUplKSzVyPUGuOFE4PzRizszN MXTTRW5ITVJ?
BHY NYGw[YV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHD[WdKSzVyPUGuOFY6OjNizszN M1vGfnNCVkeHUh?=
BB65-RCC NIrGNYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTFwNUC1Nlgh|ryP NV3ERXR2W0GQR1XS
HN MoPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTFwNUSwO|Eh|ryP NFjmOHVUSU6JRWK=
NCI-H441 MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTFwNUS5NFch|ryP MmL3V2FPT0WU
RPMI-8866 NV;TTFA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvsfJJqUUN3ME2xMlU5PTB5IN88US=> MWnTRW5ITVJ?
CAL-62 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPJUG9KSzVyPUGuOlA5PjJizszN NUfx[Vd{W0GQR1XS
MG-63 M1jyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTFwNkG4NVMh|ryP MYHTRW5ITVJ?
SK-LU-1 NV7xSWFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{n3TWlEPTB;MT62NlE2OiEQvF2= MVLTRW5ITVJ?
BCPAP NGnJT4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnteow5UUN3ME2xMlY3PDV5IN88US=> MkXkV2FPT0WU
22RV1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{i1eGlEPTB;MT62O|g1OyEQvF2= MWHTRW5ITVJ?
T47D NUHxU2YzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnhe3V3UUN3ME2xMlY5ODZzIN88US=> MmfEV2FPT0WU
MSTO-211H NYT5dWJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HhPWlEPTB;MT62PVYxOyEQvF2= NXTpZlQ1W0GQR1XS
DEL MlLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnOdXF{UUN3ME2xMlcxOjd|IN88US=> M4O4TXNCVkeHUh?=
H4 MoXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mon5TWM2OD1zLkezNlEzKM7:TR?= MnT4V2FPT0WU
CAL-51 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz5TWM2OD1zLke0PFU2KM7:TR?= MnS2V2FPT0WU
ABC-1 NUP0[HZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nlZWlEPTB;MT63PFU5OiEQvF2= M1HpZnNCVkeHUh?=
MZ2-MEL MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHJdI5KSzVyPUGuO|k2PDJizszN MWjTRW5ITVJ?
YKG-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTFwOEGwOlEh|ryP NWLqU5l4W0GQR1XS
KM12 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\6SGhyUUN3ME2xMlgyPjB{IN88US=> MWPTRW5ITVJ?
L-363 NF\uUlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HGV2lEPTB;MT64O|QyOiEQvF2= M3X0cHNCVkeHUh?=
KU812 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTFwOEmyPFIh|ryP MlzxV2FPT0WU
LOXIMVI M4e4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrTOWVPUUN3ME2xMlkyOjJ6IN88US=> NIn0fpdUSU6JRWK=
G-401 MojWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\Xc3BKSzVyPUGuPVI1OjhizszN M3nhSHNCVkeHUh?=
SW780 NEnrbYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml63TWM2OD1zLkm2NlQ3KM7:TR?= MkPVV2FPT0WU
SW872 NUHrd29YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XON2lEPTB;MT65PFM{KM7:TR?= NYjFOVdpW0GQR1XS
NB7 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HaU2lEPTB;MT65PVMzOyEQvF2= NYiwcGc2W0GQR1XS
T98G MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIq3b2lKSzVyPUKuNFA3PjZizszN MYTTRW5ITVJ?
SW1710 Mlv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH[2SXhKSzVyPUKuNFY6PDVizszN M3\TfnNCVkeHUh?=
NCI-H1573 NIqxR3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TkT2lEPTB;Mj6wO|I6QCEQvF2= M1SzS3NCVkeHUh?=
KE-37 NGjDSGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvhUGJKSzVyPUKuNFg6PTFizszN M1\DS3NCVkeHUh?=
786-0 NHmyZXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPBTWM2OD1{LkG1OFM6KM7:TR?= MXnTRW5ITVJ?
SAS MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfCZXFKSzVyPUKuNlA{PzRizszN MkfmV2FPT0WU
CAL-54 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\0TWM2OD1{LkKwOFE{KM7:TR?= NXO1bpBiW0GQR1XS
SF268 MnjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HqSGlEPTB;Mj6yN|EzOiEQvF2= M1XjVHNCVkeHUh?=
SW620 NHzUUYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4izb2lEPTB;Mj6yOlE3QSEQvF2= NXjGPHNWW0GQR1XS
MN-60 NWjESlIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3SyUWlEPTB;Mj6zNVA3KM7:TR?= NHqwR29USU6JRWK=
EFO-27 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jNfGlEPTB;Mj6zNlA2QCEQvF2= NYO4d284W0GQR1XS
NCI-H747 MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\TeZc4UUN3ME2yMlMzOTl7IN88US=> MoDOV2FPT0WU
HCC2218 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTJwM{WzO|Qh|ryP M1HhVHNCVkeHUh?=
MIA-PaCa-2 Mn\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjvSWVKSzVyPUKuN|Y1OzdizszN NYW1NoFMW0GQR1XS
SJSA-1 NVnWc|VyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofsTWM2OD1{LkO3O|k3KM7:TR?= M2r2cXNCVkeHUh?=
RKO MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LGTWlEPTB;Mj6zPFQ6PiEQvF2= NVzPVo9NW0GQR1XS
NB6 NXqyUHdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnr2TWM2OD1{LkSwN|c1KM7:TR?= M2TGT3NCVkeHUh?=
ES4 M2DJOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3T2TGlEPTB;Mj60OVQzOiEQvF2= NFPlU3JUSU6JRWK=
EGI-1 NX3EZ3hKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LacGlEPTB;Mj60Olg5OyEQvF2= NVT0TotJW0GQR1XS
CTV-1 NIDqXIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nR[WlEPTB;Mj61Nlc4OyEQvF2= MmXOV2FPT0WU
NCI-H1355 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYThNlRPUUN3ME2yMlU2QTVzIN88US=> Mn;KV2FPT0WU
GT3TKB M{n5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXQU|hZUUN3ME2yMlU6OTl7IN88US=> NYXhOVZUW0GQR1XS
SK-HEP-1 NULGRo13T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2CxdGlEPTB;Mj61PVI3PiEQvF2= MWjTRW5ITVJ?
GAMG MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF:xXXlKSzVyPUKuOVk{QTRizszN MUnTRW5ITVJ?
SK-MES-1 MkXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XOS2lEPTB;Mj62NVgxOyEQvF2= NGTzT2ZUSU6JRWK=
RO82-W-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorJTWM2OD1{Lk[yNFU4KM7:TR?= MmXpV2FPT0WU
ECC10 M4TEemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHVPHZ1UUN3ME2yMlcxOjB4IN88US=> NEDuWWVUSU6JRWK=
MCF7 MmHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoX1TWM2OD1{LkexOFY1KM7:TR?= MUHTRW5ITVJ?
D-283MED NVLzbm83T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmW3TWM2OD1{LkeyOFMh|ryP NXjQPW5IW0GQR1XS
RPMI-7951 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnIOFFxUUN3ME2yMlc2Pjl2IN88US=> M3PwcnNCVkeHUh?=
Ramos-2G6-4C10 NVLUUWVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3BNHRQUUN3ME2yMlc4ODl7IN88US=> MXrTRW5ITVJ?
KGN NGPtWmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTJwOEG4PFQh|ryP NWLPOI54W0GQR1XS
NUGC-3 NXzPPVZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTJwOEK1NFUh|ryP MmfpV2FPT0WU
NCI-H292 M1fJc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmO4TWM2OD1{Lki1NFU{KM7:TR?= MnPCV2FPT0WU
Becker NHPHSJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETkSGZKSzVyPUKuPVU5OzJizszN M1rZcHNCVkeHUh?=
NCI-H1299 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknJTWM2OD1|LkC1NlY{KM7:TR?= NWDHSINqW0GQR1XS
ETK-1 MkPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTZUI9rUUN3ME2zMlA2PDNizszN MUHTRW5ITVJ?
TK10 M{HDd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW[3dJgyUUN3ME2zMlIxOTZ3IN88US=> M{WyVnNCVkeHUh?=
VMRC-RCZ NV7qWFllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLETWM2OD1|LkO2OFg5KM7:TR?= Ml\aV2FPT0WU
YH-13 MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTNwNESwO|kh|ryP NXHSSGlzW0GQR1XS
DU-145 NWLFblJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3KzOGlEPTB;Mz60OlI3QSEQvF2= MkHhV2FPT0WU
SW1088 M4jGXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfnTWM2OD1|LkS3OFch|ryP NWDmfnJwW0GQR1XS
HOP-92 Mn7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfQTWM2OD1|LkWwN|QzKM7:TR?= M2WyNHNCVkeHUh?=
KP-N-YS MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVi1NWdTUUN3ME2zMlYzOTN7IN88US=> MVXTRW5ITVJ?
NCI-H460 NXG1N3FPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYf0RZdIUUN3ME2zMlY3PzNizszN MWjTRW5ITVJ?
U-2-OS NGXGO|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXXTWM2OD1|LkeyOVM2KM7:TR?= MoeyV2FPT0WU
A101D MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTNwN{[5N|Yh|ryP MUHTRW5ITVJ?
MDA-MB-231 NWDBVok5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHPTWM2OD1|LkixPVUyKM7:TR?= M{LYc3NCVkeHUh?=
IST-MES1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonITWM2OD1|LkizNkDPxE1? NVfWNHNjW0GQR1XS
COR-L105 NEDvOYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHROI9KSzVyPUSuNFE5KM7:TR?= M4LQUXNCVkeHUh?=
NCI-H1437 NIX6boFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITJT|VKSzVyPUSuNFI{ODJizszN NILjd3RUSU6JRWK=
CAL-85-1 M17WZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXpeGlKUUN3ME20MlAzPDZzIN88US=> MkjHV2FPT0WU
MZ1-PC NWD3cmpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoGyTWM2OD12LkG4OVU3KM7:TR?= M{HCXHNCVkeHUh?=
VM-CUB-1 MonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[wTWM2OD12LkOxNlg1KM7:TR?= MljIV2FPT0WU
CHL-1 M2Po[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTRwM{KxOlkh|ryP M33hOHNCVkeHUh?=
MDA-MB-361 NEDFfphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXS4RWFjUUN3ME20MlM{OTV|IN88US=> NIHGd4JUSU6JRWK=
NCI-H661 NXyxZ5NGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTRwNUCwPVIh|ryP NGP6UGRUSU6JRWK=
EW-11 NH\OT49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTRwNUKyN|Eh|ryP NEfHbHhUSU6JRWK=
BEN NGLXVI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHYTWM2OD12LkWyPFE2KM7:TR?= NYTjU5ZbW0GQR1XS
BFTC-909 MlTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;wUWZKSzVyPUSuOVYzPzVizszN MoXYV2FPT0WU
NCI-H2087 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1foRmlEPTB;ND61PFE3PCEQvF2= M1LxTXNCVkeHUh?=
RVH-421 NUfN[Yg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPuT2NKSzVyPUSuOlY3QSEQvF2= MlzIV2FPT0WU
P30-OHK MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTRwNkiwNFgh|ryP M1PtU3NCVkeHUh?=
NCI-H28 MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHa[WdPUUN3ME20MlgyPjZzIN88US=> NILsZ|JUSU6JRWK=
ES6 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTRwOEOwNVYh|ryP M4H2S3NCVkeHUh?=
769-P NGDjXZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTRwOEW5NlYh|ryP MmHXV2FPT0WU
OE33 M{PHXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLDTWM2OD12Lki4NVYyKM7:TR?= NXjx[nJ[W0GQR1XS
SW982 NGXCU5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HiVWlEPTB;ND65OVA3OSEQvF2= M3G4bXNCVkeHUh?=
A388 MnS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULufm1yUUN3ME21MlAzQTh|IN88US=> NFLMN5BUSU6JRWK=
TI-73 M{XkT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUK1bIFtUUN3ME21MlA3OTl2IN88US=> NWPFVm1xW0GQR1XS
HCT-116 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\kcmFJUUN3ME21MlA6QDh7IN88US=> MUfTRW5ITVJ?
HuP-T3 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofHTWM2OD13LkG4O|A6KM7:TR?= NWL3XpZKW0GQR1XS
G-402 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4L0TGlEPTB;NT6xPVQyPiEQvF2= MnHuV2FPT0WU
NCI-H1792 M3:zN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XjWmlEPTB;NT6yOFYzOiEQvF2= M2rJenNCVkeHUh?=
NCI-H209 M4f4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIraW2VKSzVyPUWuNlU6PDJizszN MYPTRW5ITVJ?
NCI-H1650 NWW1cI9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUC1UHd5UUN3ME21MlMxPjN2IN88US=> Mn;IV2FPT0WU
LCLC-97TM1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vEbGlEPTB;NT6zNVgxQCEQvF2= MUjTRW5ITVJ?
S-117 M3GxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLyT41KSzVyPUWuN|Y6PzZizszN NHfBT4hUSU6JRWK=
GI-ME-N NX3OdI54T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PyXGlEPTB;NT6zPVY5OSEQvF2= NITiO41USU6JRWK=
NCI-H2122 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\lfG9KSzVyPUWuOFk{QTdizszN NGPxTYtUSU6JRWK=
NCI-H1793 Mk\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vaZ2lEPTB;NT62O|U6OyEQvF2= M2TRT3NCVkeHUh?=
C2BBe1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TCcGlEPTB;NT63NFA5QCEQvF2= MUPTRW5ITVJ?
TE-12 MlLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXGbYRoUUN3ME21MlgxPTV4IN88US=> MkDMV2FPT0WU
LCLC-103H NFfx[mNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3SzbGlEPTB;NT65NVch|ryP MmjVV2FPT0WU
A673 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjVN|NKSzVyPUWuPVE6OzJizszN Ml7BV2FPT0WU
BB30-HNC NE\6ZlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorOTWM2OD13Lkm4N|Yh|ryP NX65VIY{W0GQR1XS
SF295 M3jP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTZwMEC0NlIh|ryP MXrTRW5ITVJ?
KU-19-19 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{X4SGlEPTB;Nj6wNVc{OSEQvF2= M3m3SnNCVkeHUh?=
CFPAC-1 NXLmXpc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Ky[GlEPTB;Nj6wOFQ1OyEQvF2= NVPDPWd6W0GQR1XS
LoVo MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTZwMEWwOlMh|ryP MnPIV2FPT0WU
8505C NGDVO4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlq0TWM2OD14LkC3OVc{KM7:TR?= MVjTRW5ITVJ?
GMS-10 MmnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjtSolxUUN3ME22MlE2ODB{IN88US=> M1PoVXNCVkeHUh?=
Ca9-22 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTZwMU[3NUDPxE1? NVPTdlBrW0GQR1XS
DOK Ml;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWThc4lsUUN3ME22MlIzODd{IN88US=> MXvTRW5ITVJ?
FADU NW\LXVNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nNSWlEPTB;Nj6yOlA{QSEQvF2= MlW5V2FPT0WU
BxPC-3 NIHVbJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIC1XIRKSzVyPU[uNlc{OiEQvF2= MlXGV2FPT0WU
CAL-33 NF7FfVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\EdJRKSzVyPU[uNlkzODFizszN MoTaV2FPT0WU
SHP-77 NX60PFFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;ZSlJKSzVyPU[uN|E2OTJizszN MX\TRW5ITVJ?
LXF-289 M{frT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTZwM{O0OVUh|ryP NUXOXm85W0GQR1XS
GB-1 NYnYXIZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIf6OodKSzVyPU[uN|gzKM7:TR?= MXjTRW5ITVJ?
KS-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHroVohKSzVyPU[uN|g1PDdizszN NEfCcZFUSU6JRWK=
D-502MG MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7RTWM2OD14LkSyN|c3KM7:TR?= MnfUV2FPT0WU
LAN-6 M4PySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mni2TWM2OD14LkWxNFI{KM7:TR?= Mn\rV2FPT0WU
H-EMC-SS M374NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXBTWM2OD14LkW2NVQ4KM7:TR?= MVTTRW5ITVJ?
LC-2-ad NIrCNXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTZwNkCwO|Yh|ryP NEXoSZBUSU6JRWK=
NCI-H1693 NYS5OHR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\LTWM2OD14Lk[yNlE2KM7:TR?= MWnTRW5ITVJ?
SK-N-FI MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnUeINKSzVyPU[uO|UxPDRizszN M{\Zc3NCVkeHUh?=
D-423MG M{XId2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPxTWM2OD14Lke2NVE4KM7:TR?= M1jHXHNCVkeHUh?=
KNS-42 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVG5e3BDUUN3ME22Mlc5OTl5IN88US=> MX;TRW5ITVJ?
GCT MoLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3RRVRKUUN3ME22Mlk{QCEQvF2= MmThV2FPT0WU
DSH1 NITmT3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3vdXpVUUN3ME23MlA3OzNizszN NXPrd5lbW0GQR1XS
D-247MG NVXsT3d7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTdwMEe4PFEh|ryP M2q5UHNCVkeHUh?=
NCI-SNU-5 M4T0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHkSIQ4UUN3ME23MlE5OzdzIN88US=> NGTj[2xUSU6JRWK=
TE-6 NITTO4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTdwMkC2NFEh|ryP MXvTRW5ITVJ?
NOMO-1 NECxZZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjYelVKSzVyPUeuNlIyOjdizszN MlrYV2FPT0WU
NB17 MmixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTdwM{CzNFkh|ryP Mnm1V2FPT0WU
EW-22 M3rLZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkGwTWM2OD15LkO0N|Q5KM7:TR?= MoL3V2FPT0WU
EW-13 M2nlfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULFO4JmUUN3ME23MlM2OTZ{IN88US=> NFrqc4NUSU6JRWK=
DOHH-2 M2rBbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\FRWlEPTB;Nz60OFAzKM7:TR?= MWPTRW5ITVJ?
TGBC1TKB MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVe4OIpGUUN3ME23MlQ6QDl7IN88US=> MXzTRW5ITVJ?
GR-ST MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TEUWlEPTB;Nz61NlU6PCEQvF2= MkPXV2FPT0WU
KYSE-520 NV;DUotsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrCZYNrUUN3ME23MlU2PTF3IN88US=> MkPSV2FPT0WU
CAPAN-1 NY\oSHh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jkRmlEPTB;Nz61PVUyKM7:TR?= MkTOV2FPT0WU
HCE-4 NX\GXFJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWe2cFJCUUN3ME23MlYzOjd7IN88US=> M1npXXNCVkeHUh?=
MLMA Mm\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYO0VpBGUUN3ME23MlYzQTV5IN88US=> MkDGV2FPT0WU
HT-144 M3zkT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTdwNkWzOlgh|ryP NHLZcXBUSU6JRWK=
KYSE-180 MoG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTdwN{GxOlkh|ryP NX3PXWdqW0GQR1XS
TE-5 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDlTWM2OD15Lkm1PVcyKM7:TR?= M2nufnNCVkeHUh?=
IGROV-1 NVHzXpIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUna[WJNUUN3ME23Mlk5PTVzIN88US=> NXPTOGtEW0GQR1XS
NCI-H1581 NFGyUZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPsNpBKSzVyPUiuNFEzKM7:TR?= NU\vPZI2W0GQR1XS
SW1990 MojVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRThwMES2OVkh|ryP MkTOV2FPT0WU
EFM-19 NVno[HlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFS3SmhKSzVyPUiuNFg2PDVizszN M2i5O3NCVkeHUh?=
OGR-1 MnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILWZZFKSzVyPUiuOFMxOjNizszN MnXaV2FPT0WU
U-118-MG NFL1XGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonCTWM2OD16LkSzOFY{KM7:TR?= M3rOdnNCVkeHUh?=
SK-OV-3 MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXST|gxUUN3ME24MlQ3PzZ3IN88US=> M{\aRnNCVkeHUh?=
KNS-62 NVTiOZBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jzUWlEPTB;OD61NVc3OSEQvF2= MYfTRW5ITVJ?
GOTO NX3VXmlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\NNpFIUUN3ME24MlU4PjN3IN88US=> M4LBPXNCVkeHUh?=
8305C MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFT5O4pKSzVyPUiuO|A1QDRizszN MlrEV2FPT0WU
RPMI-2650 MlLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYT3fVc4UUN3ME24MlcyQTV3IN88US=> Mnv3V2FPT0WU
NEC8 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPITWM2OD16Lke0N|A4KM7:TR?= NV7Zb2hlW0GQR1XS
KYSE-450 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRThwOE[1OFgh|ryP MW\TRW5ITVJ?
RMG-I M1G2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\pN2w1UUN3ME25MlE1ODV6IN88US=> MlzjV2FPT0WU
CAKI-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrmO5piUUN3ME25MlMyQTd7IN88US=> Mnq0V2FPT0WU
KYSE-510 M3fOZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnjeWhKSzVyPUmuN|U4PzhizszN NVfqRYxVW0GQR1XS
A4-Fuk NYD3dHI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFj1XIxKSzVyPUmuN|Y4ODFizszN NFnpTpRUSU6JRWK=
AN3-CA M4rxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofaTWM2OD17LkS1OFQ1KM7:TR?= Mn\6V2FPT0WU
SK-N-DZ MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHiyPVVKSzVyPUmuO|I5PDlizszN NV22ZY5kW0GQR1XS
HSC-2 NYD2O3FST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17LU2lEPTB;OT63OlYzQSEQvF2= M2fUdnNCVkeHUh?=
EW-1 MnHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnSTWM2OD17Lke5N|Y6KM7:TR?= NX;oRoVxW0GQR1XS
D-566MG MkTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTlwOEO2OlQh|ryP MYPTRW5ITVJ?
COLO-792 NILZVodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTlwOUi3OFYh|ryP MWjTRW5ITVJ?
TE-10 NF;HNWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTZTWM2OD1zMD6wN|k3KM7:TR?= NYfnRpYyW0GQR1XS
NCI-H650 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4OwZWlEPTB;MUCuOFI5PiEQvF2= MW\TRW5ITVJ?
U-266 NWSyXIpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XGPGlEPTB;MUCuOFU2KM7:TR?= M3\xXXNCVkeHUh?=
Detroit562 NYLzc2hJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmi3TWM2OD1zMT6wOVE2KM7:TR?= M4TBd3NCVkeHUh?=
NH-12 NUTrT4NxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULzOFlvUUN3ME2xNU4yPDR4IN88US=> NGf1NmJUSU6JRWK=
CO-314 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LHOmlEPTB;MUGuNlg1OiEQvF2= NHvMT|ZUSU6JRWK=
IST-MEL1 NYP0cFQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLFWXUzUUN3ME2xNU42OzJ|IN88US=> MVrTRW5ITVJ?
KNS-81-FD NILnZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DJdmlEPTB;MUGuOVUzPyEQvF2= MWLTRW5ITVJ?
SW1463 MmH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVWxflBFUUN3ME2xNU42QTh7IN88US=> MXXTRW5ITVJ?
NCI-H23 NHXVeJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTFzLk[1OVIh|ryP NYPKT|dMW0GQR1XS
SK-MEL-2 M1i1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILFOlJKSzVyPUGxMlcyQTdizszN M2XETXNCVkeHUh?=
NB13 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTF{LkG0PVUh|ryP MlXTV2FPT0WU
Daoy MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTF{LkK4OVYh|ryP NFvteFVUSU6JRWK=
NCI-H1623 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTF{LkO4NFEh|ryP NWLsXmZZW0GQR1XS
NMC-G1 M1foemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2L3U2lEPTB;MUKuO|E4KM7:TR?= MmXPV2FPT0WU
DK-MG M1[2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTF{Lkm0PFIh|ryP NWDSN2gyW0GQR1XS
TCCSUP MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DVcGlEPTB;MUOuNVI5PCEQvF2= MUjTRW5ITVJ?
SCC-15 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TRcGlEPTB;MUOuNlY2OSEQvF2= NYrSNGJnW0GQR1XS
NOS-1 NIjQRo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXe3ZZZoUUN3ME2xN{4zQDl|IN88US=> M{nwO3NCVkeHUh?=
RH-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTF|LkOwN|ch|ryP MkHKV2FPT0WU
SK-MEL-3 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmqyTWM2OD1zMz6zO|I5KM7:TR?= MoTXV2FPT0WU
NB5 NIDtPG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nzWGlEPTB;MUOuOFA3PyEQvF2= NGPvOYVUSU6JRWK=
SNU-387 M2PpOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\nUG1YUUN3ME2xN{42ODd{IN88US=> MlTDV2FPT0WU
CAL-120 MoHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTF|Lk[3NVgh|ryP NVz6UnBuW0GQR1XS
Mo-T MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M36ySmlEPTB;MUOuO|A4KM7:TR?= NFjUcWhUSU6JRWK=
LNCaP-Clone-FGC M{XnS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jY[2lEPTB;MUOuO|k6OiEQvF2= MWjTRW5ITVJ?
CAN MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LDeWlEPTB;MUSuNFI5QCEQvF2= MnW0V2FPT0WU
SK-MEL-30 NYHNWmpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTzT3lyUUN3ME2xOE4xPjNizszN MVrTRW5ITVJ?
COLO-678 M3;HWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTF2LkC4NlIh|ryP MlS4V2FPT0WU
SCC-9 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTF2LkGwNlEh|ryP NIjy[npUSU6JRWK=
KINGS-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrIW|d3UUN3ME2xOE4yPDB{IN88US=> NWH4WpdiW0GQR1XS
SL-513 Mlf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHNUG1RUUN3ME2xOE4yQDdizszN MknMV2FPT0WU
HLE M2X0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\Oc5NKSzVyPUG0MlM5PTJizszN MonEV2FPT0WU
SW1573 NEC2bnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTF2LkS0N|Uh|ryP NH3PcGxUSU6JRWK=
KYSE-140 MnyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PGfmlEPTB;MUSuOlMzPyEQvF2= NFrVVXBUSU6JRWK=
SK-PN-DW MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLyTWM2OD1zND64NFAyKM7:TR?= M{fHeHNCVkeHUh?=
A253 MlntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljQTWM2OD1zNT6wOlI2KM7:TR?= M4jX[3NCVkeHUh?=
CAL-12T MlXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk[wTWM2OD1zNT60OlYzKM7:TR?= M1qyRXNCVkeHUh?=
COLO-679 MmD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\rN5R2UUN3ME2xOU44Pjh|IN88US=> NWnm[HRGW0GQR1XS
UACC-257 NIjpT4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mle4TWM2OD1zNj6xNlAyKM7:TR?= MWrTRW5ITVJ?
U-87-MG NHWxfZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rjdWlEPTB;MU[uN|UzOyEQvF2= NGLEcW5USU6JRWK=
HCC1806 M4\LT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moq2TWM2OD1zNj63NFcyKM7:TR?= MWXTRW5ITVJ?
NCI-H2170 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPuTWM2OD1zNz6yOFQ5KM7:TR?= MoDjV2FPT0WU
AGS M1HqfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHTTWM2OD1zNz6zPFA5KM7:TR?= MmLWV2FPT0WU
MEL-HO MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrkeYJKSzVyPUG3Mlc2ODNizszN NX7UPGl{W0GQR1XS
SW48 MljSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHNUZhKSzVyPUG3Mlc4OTZizszN MnL4V2FPT0WU
HuP-T4 M4T1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoriTWM2OD1zOD6wNlA3KM7:TR?= NUL6XXg4W0GQR1XS
NCI-H720 NYHxdocyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDkTWM2OD1zOD6xOFAzKM7:TR?= NFn2RnJUSU6JRWK=
RCC10RGB M3GzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnZc4pKSzVyPUG4MlE3QTdizszN NIHaS4RUSU6JRWK=
HD-MY-Z MoHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PqUGlEPTB;MUiuNlI2PCEQvF2= NYGwbWhQW0GQR1XS
A427 M1jMfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvkc3FlUUN3ME2xPE42ODl2IN88US=> NH3IWoVUSU6JRWK=
HCC2998 MnHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGT6V2NKSzVyPUG4MlYxPTFizszN MlnTV2FPT0WU
EPLC-272H MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDWVIFKSzVyPUG5MlA1OzRizszN NX7jNY1NW0GQR1XS
C32 NGLLW4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjoeWV[UUN3ME2xPU4xPDVizszN NHLVNZNUSU6JRWK=
UMC-11 NIK3XIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfqfohKSzVyPUG5MlIyOjNizszN NHrCN4JUSU6JRWK=
CaR-1 NUfCXmhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnsOnFLUUN3ME2xPU43QDB2IN88US=> MVnTRW5ITVJ?
KYSE-410 NHz1UJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTF7LkmxN|kh|ryP MlHGV2FPT0WU
HuCCT1 NYLRXmRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTJyLk[yPVQh|ryP NGfvSphUSU6JRWK=
LB996-RCC MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3f5UmlEPTB;MkCuO|E3QCEQvF2= M3q1eHNCVkeHUh?=
KYSE-70 MofOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTieJFQUUN3ME2yNE45ODV7IN88US=> NELmeoJUSU6JRWK=
CAL-72 M3;2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPPXJpXUUN3ME2yNE46OTVizszN MUDTRW5ITVJ?
Capan-2 M3PG[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\HcYg5UUN3ME2yNU4xPDF|IN88US=> M363NXNCVkeHUh?=
PANC-08-13 NYXrW5JvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnNUYZKSzVyPUKxMlI2OTVizszN MUfTRW5ITVJ?
SBC-1 M{[wSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFv4TFdKSzVyPUKxMlMxQDFizszN NWTvTGk2W0GQR1XS
MFM-223 NV7jenk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTJzLkOzOFIh|ryP MWnTRW5ITVJ?
BB49-HNC Ml3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3DTWM2OD1{MT61O|E3KM7:TR?= NFu1Z2ZUSU6JRWK=
SH-4 MkLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXETWM2OD1{MT62OlE5KM7:TR?= NGPaXohUSU6JRWK=
HuO9 M3LKVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nTemlEPTB;MkGuPVgzPSEQvF2= NYfhPZI2W0GQR1XS
AM-38 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2q5[WlEPTB;MkKuNFQ5PSEQvF2= NUHhWJRxW0GQR1XS
A431 NWXjbphwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH33PJJKSzVyPUKzMlIyOTlizszN M1e2d3NCVkeHUh?=
YAPC NXrpSnNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3zPYttUUN3ME2yN{4zPjVzIN88US=> Mo\XV2FPT0WU
LU-139 NYGwRXZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1S4cGlEPTB;MkOuOFgxQSEQvF2= NHvyXWJUSU6JRWK=
HEC-1 NIDJZ4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\KUGlEPTB;MkOuOFk{PyEQvF2= MXjTRW5ITVJ?
SCC-25 NHW0[IpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPnWZNvUUN3ME2yOE4{ODB4IN88US=> MVPTRW5ITVJ?
HT-29 NWL1RYd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PhUmlEPTB;MkSuN|gzOyEQvF2= M{nQRXNCVkeHUh?=
PC-14 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLqUXF5UUN3ME2yOE43PTdzIN88US=> M2XZVnNCVkeHUh?=
Calu-6 NYHLT2J3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;1ZnVKSzVyPUK1MlUxPzFizszN MlT1V2FPT0WU
SJRH30 NYTEW45HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTLN2lwUUN3ME2yOU43PDl4IN88US=> NWHnNW1JW0GQR1XS
ChaGo-K-1 M4jNU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTJ4LkG2Nlkh|ryP MWjTRW5ITVJ?
IA-LM M{WzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzkTWM2OD1{Nj6zOlQ2KM7:TR?= NIXWNJpUSU6JRWK=
GP5d NVnwdWlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTzTWM2OD1{Nj60OFkyKM7:TR?= M4XISHNCVkeHUh?=
NCI-H2291 NWDv[3JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfXRZZKSzVyPUK2MlY2PDFizszN NIrCSHZUSU6JRWK=
BALL-1 NXHYW4JtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jISGlEPTB;Mk[uPVM6PyEQvF2= NHPpd|JUSU6JRWK=
HCC1954 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTJ4Lkm4NFgh|ryP MonrV2FPT0WU
NCI-H2452 M{XV[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVH6fmZbUUN3ME2yO{41OTZ|IN88US=> NInBOJpUSU6JRWK=
LU-99A NXzWPWdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrKTWM2OD1{Nz61OVgzKM7:TR?= Mn;OV2FPT0WU
NTERA-S-cl-D1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULjeoZDUUN3ME2yO{44Ojl7IN88US=> NYrHc2NoW0GQR1XS
PANC-10-05 Mo\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTJ5Lke3O|Uh|ryP M2\YUXNCVkeHUh?=
NCI-H2405 NICzeWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LJU2lEPTB;MkeuPVM5PyEQvF2= M13USnNCVkeHUh?=
MDA-MB-415 NYr2SmRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDXRoFKSzVyPUK4MlQyOzdizszN MnPPV2FPT0WU
NCI-H2342 NXO4bphFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTJ6LkWyPFEh|ryP NFvucodUSU6JRWK=
TGBC24TKB NFK2dHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTJ6LkexNVch|ryP Mkm4V2FPT0WU
LU-134-A NWfyfmFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIX0c3hKSzVyPUK4MlkzPjFizszN M{jxSXNCVkeHUh?=
SCC-4 NXHEdZZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIr1RmJKSzVyPUOxMlA1QTRizszN NVfIPW1NW0GQR1XS
Saos-2 NVGwPYkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXXTWM2OD1|MT65N|A3KM7:TR?= M1TwWXNCVkeHUh?=
RERF-LC-MS NVnESlQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1m0XmlEPTB;M{KuPFI{OSEQvF2= NYnIN5lSW0GQR1XS
M14 NGfxe5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LPR2lEPTB;M{KuPVc3PCEQvF2= MXnTRW5ITVJ?
HPAF-II Mm\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDQ[G9RUUN3ME2zN{42ODFzIN88US=> NWDZVmJCW0GQR1XS
NCI-H1755 M{TGcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;BTWM2OD1|ND6zN|A2KM7:TR?= MnmyV2FPT0WU
D-392MG MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fuNmlEPTB;M{WuPFY4PCEQvF2= MVzTRW5ITVJ?
A704 NHf0cWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTN4LkC0Nlch|ryP MkCzV2FPT0WU
CP50-MEL-B MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTOXVR3UUN3ME2zOk4yQTFzIN88US=> MmD1V2FPT0WU
EW-18 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTlc2tKSzVyPUO2MlQ2OiEQvF2= MUPTRW5ITVJ?
WM-115 MknXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTN4LkiwPVkh|ryP NX3Qd5JMW0GQR1XS
LU-65 M3PRdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLqTGRrUUN3ME2zO{4yPDF5IN88US=> NYr3PG1PW0GQR1XS
NCI-H1563 NHjkXplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnZTWM2OD1|Nz6yOFg1KM7:TR?= NHjRNJlUSU6JRWK=
DBTRG-05MG Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTN6LkC2PVEh|ryP MoKxV2FPT0WU
NCI-H630 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml2wTWM2OD1|OD60O|E1KM7:TR?= M{nRe3NCVkeHUh?=
NCI-H1155 NYPxS5Y1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILK[HJKSzVyPUO5MlI1OiEQvF2= NVjofmM{W0GQR1XS
OVACR-3 M{fXSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTN7LkmxPVUh|ryP NVXJU4FSW0GQR1XS
OAW-42 M3jTS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTRyLkSyOVgh|ryP M1OxPHNCVkeHUh?=
JVM-2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoX5TWM2OD12MT6yOFE2KM7:TR?= NVfVPXVIW0GQR1XS
C3A NYfOcHBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37COWlEPTB;NEGuN|Q1PyEQvF2= MXLTRW5ITVJ?
HT55 M3LSPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPQZ4NKSzVyPUSyMlI5PDFizszN M2HhfXNCVkeHUh?=
OVCAR-4 NX3rT2YxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnO1TWM2OD12Mj6yPVc1KM7:TR?= Mme3V2FPT0WU
MEG-01 NG[yVXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTR{LkS2NVYh|ryP NYi0VllzW0GQR1XS
NCI-H82 NFK3XHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3OwbGlEPTB;NEOuPVg6OiEQvF2= MnWyV2FPT0WU
JEG-3 Mmj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnH0TWM2OD12ND65OFch|ryP NUC2U4lYW0GQR1XS
BPH-1 MkTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33tN2lEPTB;NE[uN|k6QCEQvF2= NX\HNI5tW0GQR1XS
MPP-89 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTR5LkK4PVgh|ryP MkPGV2FPT0WU
ALL-PO MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjDWoJ[UUN3ME20O{41OTh6IN88US=> MVfTRW5ITVJ?
HT M3;UZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTR5LkS5NkDPxE1? NH;oNVJUSU6JRWK=
NCI-H2347 MnnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fyR2lEPTB;NEiuNFcyPSEQvF2= MYTTRW5ITVJ?
A2780 NFzWNVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfqTWM2OD12OT60NlI5KM7:TR?= MYLTRW5ITVJ?
KARPAS-299 M1vER2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGWyc5dKSzVyPUS5MlUyOTlizszN M172e3NCVkeHUh?=
NCI-H1651 MlPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHlbVNKSzVyPUS5Mlg5OjFizszN NXHZcFhOW0GQR1XS

... Click to View More Cell Line Experimental Data

体内研究 150 mg/kg PD 0332991处理 MDA-MB-435移植瘤完全抑制肿瘤。在多种人类肿瘤移植瘤中,PD 0332991也显示广谱抗癌活性,通过除去血管中p-Rb和增殖Marker Ki-67,且调节基因使其处于E2F转录水平控制。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

Cdk实验:

PD0332991溶解在DMSO中。在96孔板上进行CDK 实验。通过杆状病毒感染,所有的CDK-cyclin 激酶复合体 在昆虫细胞中表达。实验底物为与GST融合的一段pRb。每孔体积为0.1 ml,包含:终浓度为20 mm Tris-HCl(pH 为7.4), 50 mmNaCl, 1 mm二硫苏糖醇, 10 mmMgCl2, 25 μm ATP (用于CDK4-cyclin D1, CDK6-cyclin D2,和CDK6-cyclin D3)或12 μm ATP (用于CDK2-cyclin E, CDK2-cyclin A, 和CDC2-cyclin B),0.25 μCi [γ-32P]ATP, 20 ng 酶, 1 μg GST·RB-Cterm, 及PD 0332991 (0.001-0.1μM)。除了[γ-32P]ATP的所有混合物加到孔中,放在搅拌器上搅拌2分钟。加入 [γ-32P]ATP开始反应, 在25 oC下温育15分钟。加入0.1 ml 20% 三氯乙酸终止反应, 在4 oC维持至少1小时,使底物沉淀。用0.2 ml 10%三氯乙酸冲洗5次,用β-计数器板测定掺入的放射性。
细胞实验:

[1]

+ 展开
  • Cell lines: MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM,和K562细胞
  • Concentrations: 0.01-1 μM
  • Incubation Time: 24小时
  • Method:

    肿瘤细胞包括MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM,及K562按每孔2×104个细胞接种在96孔板上,温育过夜。加入PD 0332991 (0.01-1 μM) ,37oC温育24小时。每孔加入[14C]胸甘(0.1 μCi) ,进行同位素示踪,持续72小时。用β-计数器板测定掺入的放射性。


    (Only for Reference)
动物实验:

[1]

+ 展开
  • Animal Models: 携带晚期人类肿瘤移植瘤,包括结肠-205, MDA-MB-435 乳腺癌, SF-295 恶性胶质瘤, ZR-75-1 乳腺癌, PC-3 前列腺癌, H125 肺癌, SW-620结肠癌, H23肺癌,及MDA-MB-468 乳腺癌 (Rb 阴性)的SCID鼠
  • Formulation: 溶解在乳酸钠buffer(50 mM, pH 4.0)中
  • Dosages: 0-150 mg/kg
  • Administration: 口服饲喂
    (Only for Reference)

溶解度 (25°C)

体外 Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol Insoluble
体内 从左到右依次加入纯溶剂:
Saline
20 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 483.99
化学式

C24H29N7O2.HCl

CAS号 827022-32-2
稳定性 powder
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03007979 Not yet recruiting Breast Cancer|Breast Carcinoma|Cancer of Breast|Malignant Tumor of Breast Washington University School of Medicine February 28, 2017 Phase 2
NCT02907918 Not yet recruiting Breast Cancer|Cancer of Breast|Breast Carcinoma Washington University School of Medicine|Pfizer February 28, 2017 Phase 2
NCT01209598 Completed Sarcoma|Liposarcoma Memorial Sloan Kettering Cancer Center|Pfizer September 23, 2010 Phase 2
NCT03054363 Not yet recruiting Breast Cancer University of Colorado, Denver March 2017 Phase 1|Phase 2
NCT03024489 Not yet recruiting Head and Neck Cancer|Locally Advanced|Unresectable Mahidol University February 2017 Phase 1|Phase 2
NCT02947685 Not yet recruiting HER-2 Positive Breast Cancer|Estrogen Receptor Positive Breast Cancer Alliance Foundation Trials, LLC.|Pfizer|German Breast Group (GBG)|Fondazione Michelangelo|PrECOG, LLC.|The Australia and New Zealand Breast Cancer Trials Group (ANZBCTG)|Alliance Foundation Trials Biorepository - Washington State University|Alliance Foundation Trials Central Imaging Core Lab - Ohio State University|Mastering Breast Cancer Initiative, LLC|Mayo Clinic Statistics and Data Center|INC Research|SOLTI Breast Cancer Research Group February 2017 Phase 3

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    There are two kind of Palbociclibs available: the isethionate salt or the HCl salt. I would like to know which is the main difference between them and what are they more suitable for in terms of experiment type (cell culture or in vivo animals experiments).

  • 回答:

    This two compounds are different Palbociclib salt. S1579 is the Isethionate salt, and the S1116 is the HCl salt. you can use S1116 for oral administration while S1579 is more suitable for I.P. administration.

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

相关CDK产品

Tags: 购买Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl供应商 | 采购Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl价格 | Palbociclib (PD-0332991) HCl生产 | 订购Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID